Related Experiment Video
Updated: Feb 27, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.6K
Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics
Andreas A Argyriou1, Jordi Bruna2,3, Armando A Genazzani4
1Department of Neurology, Saint Andrew's State General Hospital of Patras, Tsertidou 1 Street, 26335, Patras, Greece.
Nature Reviews. Neurology
|July 1, 2017
Summary
Identifying genetic markers for chemotherapy-induced peripheral neurotoxicity (CIPN) remains challenging due to inconsistent study findings. This review updates pharmacogenetic research on CIPN and suggests methods to improve future study reliability.
Area of Science:
- Pharmacogenetics
- Oncology
- Neuroscience
Background:
- Genetic variation influences drug response and adverse effects, including chemotherapy-induced peripheral neurotoxicity (CIPN).
- CIPN is a severe non-haematological adverse effect of cancer treatment, necessitating risk prediction strategies.
- Despite two decades of research, a reliable genetic profile for identifying high-risk CIPN patients is still lacking.
Purpose of the Study:
- To provide a critical update on the pharmacogenetics of CIPN, focusing on studies published since 2011.
- To highlight inconsistencies in current pharmacogenetic findings for CIPN.
- To discuss strategies for enhancing the reliability of future CIPN pharmacogenetic studies.
Main Methods:
- Literature review of pharmacogenetic studies on CIPN published since 2011.
- Critical analysis of methodological flaws and assessment tool reliability in existing studies.
- Synthesis of current knowledge and identification of research gaps.
Main Results:
- Existing pharmacogenetic data for CIPN is inconsistent, hindering the identification of high-risk patients.
- Methodological limitations and unreliable assessment tools contribute significantly to study inconsistencies.
- Recent research continues to explore genetic associations with CIPN, but definitive profiles are elusive.
Conclusions:
- A reliable genetic profile for predicting CIPN risk is an unmet clinical need.
- Improving study methodologies, including objective CIPN assessment, is crucial for advancing CIPN pharmacogenetics.
- Future research should focus on robust study designs to overcome current inconsistencies and establish predictive genetic markers.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
691
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
691
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
01:29Pharmacogenetics and Pharmacogenomics: Overview
74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
979
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
979
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53